Overview

BenchSci operates in the biotechnology sector, focusing on preclinical research and development. The company uses artificial intelligence and machine learning to create a detailed map of disease biology, which helps scientists understand existing research and improve their R&D efficiency. Its main product, ASCEND, is a platform that assists scientists in hypothesis generation, experimental design, and risk identification across various therapeutic areas. BenchSci aims to enhance the research process by providing tools that accelerate research and reduce risks.

Simplify's Take

What believers are saying

• $95M Series D funding boosts BenchSci's AI platform development and market reach.
• Generative AI integration enhances ASCEND's predictive capabilities for hypothesis generation.
• Recognition as a Best Workplace for Inclusion attracts top talent and fosters innovation.

What critics are saying

• 17% workforce reduction may impact morale and innovation at BenchSci.
• Heavy reliance on external funding poses financial risks if future rounds falter.
• Rapid team expansion could lead to integration challenges and inefficiencies.

What makes BenchSci unique

• BenchSci's ASCEND platform uses AI to map disease biology for drug discovery.
• ASCEND helps scientists identify risks and generate hypotheses in preclinical R&D.
• BenchSci's AI Reagent Selector improves reagent selection efficiency in drug development.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$156.6M

Below

Industry Average

Funded Over

5 Rounds

$69,670,000

Series D

May 2023

Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.

Series D Funding Comparison

Meet Average

Industry standards

Ind Avg. $77M

$49M

$50M

$69.7M

$70M

$80M

$100M

View all funding stages